CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Los Angeles |
Dr. Kathrin Plath Dr. |
New Faculty I |
In vitro reprogramming of mouse and human somatic cells to an embryonic state |
$2,229,427 |
| The Regents of the University of California on behalf of its Riverside Campus |
Dr. Douglas Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$621,639 |
| Western University of Health Sciences |
Dr. Douglas W Ethell |
New Faculty I |
ES-Derived Cells for the Treatment of Alzheimer’s Disease |
$1,401,642 |
| University of California, Davis |
Dr. Chong-Xian Pan |
New Faculty I |
Combinatorial Chemistry Approaches to Develop LIgands against Leukemia Stem Cells |
$2,386,409 |
| University of California, Los Angeles |
Dr. Hanna Mikkola |
New Faculty I |
Mechanisms of Hematopoietic stem cell Specification and Self-Renewal |
$2,286,900 |
| City of Hope, Beckman Research Institute |
Dr. Tiziano Barberi |
New Faculty I |
Skeletal muscle development from hESC and its in vivo applications in animal models of muscular dystrophy |
$131,840 |
| Scripps Research Institute |
Dr. Kristin K Baldwin Dr. |
New Faculty I |
Generating pluripotent cell lines from neurons. |
$2,786,560 |
| Salk Institute for Biological Studies |
Dr. Lei Wang |
New Faculty I |
Genetic Encoding Novel Amino Acids in Embryonic Stem Cells for Molecular Understanding of Differentiation to Dopamine Neurons |
$2,587,742 |
| Stanford University |
Dr. Anne Brunet |
New Faculty I |
Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
| University of California, Merced |
Dr Jennifer O Manilay |
New Faculty I |
Enhancing Survival of Embryonic Stem Cell-Derived Grafts by Induction of Immunological Tolerance |
$1,576,389 |
| University of California, Irvine |
Dr. Andrew Putnam |
New Faculty I |
A Novel Engineered Niche to Explore the Vasculogenic Potential of Embryonic Stem Cells |
$395,764 |
| Stanford University |
Dr. Joanna Wysocka PhD |
New Faculty I |
Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
| University of California, San Diego |
Dr. David Traver |
New Faculty I |
Genetic dissection of mesodermal commitment to the hematopoietic fates. |
$2,150,620 |
| University of Southern California |
Dr. Songtao Shi |
New Faculty I |
Oral and Craniofacial Reconstruction Using Mesenchymal Stem Cells |
$3,242,651 |
| Scripps Research Institute |
Dr. Sheng Ding Dr. |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
| Gladstone Institutes, J. David |
Sheng Ding PhD |
New Faculty I |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,320,101 |
| Stanford University |
Karl Deisseroth |
New Faculty I |
Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
| Stanford University |
Dr. Howard Y. Chang |
New Faculty I |
Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
| BioTime, Inc. |
Dr. Michael D West Ph.D. |
Early Translational I |
Addressing the Cell Purity and Identity Bottleneck Through Generation and Expansion of Clonal Human Embryonic Progenitor Cell Lines |
$4,721,706 |
| University of California, Davis |
Dr. Alice F Tarantal |
Early Translational I |
In Utero Model to Assess the Fate of Transplanted Human Cells for Translational Research and Pediatric Therapies |
$3,143,392 |
| Salk Institute for Biological Studies |
Dr. Inder M. Verma |
Early Translational I |
Curing Hematological Diseases |
$5,979,252 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr Evan Y Snyder |
Early Translational I |
Developmental Candidates for Cell-Based Therapies for Parkinson’s Disease (PD) |
$5,190,752 |
| Stanford University |
Dr. Jill Helms |
Early Translational I |
Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Jackson Labs |
Pali G. Kaur |
Early Translational I |
Mouse Models for Stem Cell Therapeutic Development |
$3,759,134 |
| Gladstone Institutes, J. David |
Dr. Warner C Greene |
Early Translational I |
Maximizing the Safety of Induced Pluripotent Stem Cells as an Infusion Therapy: Limiting the Mutagenic Threat of Retroelement Retrotransposition during iPSC Generation, Expansion and Differentiation |
$1,280,001 |
| Scripps Research Institute |
Dr. Martin Friedlander |
Early Translational I |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
| University of California, Los Angeles |
Dr. Gabriel H. Travis |
Early Translational I |
Development of a Stem Cell-based Transplantation Strategy for Treating Age-related Macular Degeneration |
$5,487,136 |
| Scripps Research Institute |
Dr. Jeanne F Loring |
Early Translational I |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
| ViaCyte, Inc. |
Dr. Olivia G. Kelly |
Early Translational I |
Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product |
$5,405,397 |
| Scripps Health |
Dr. Darryl D. D’Lima |
Early Translational I |
Stem Cell-Based Therapy for Cartilage Regeneration and Osteoarthritis |
$3,118,431 |
| University of California, Irvine |
Dr. Frank LaFerla |
Early Translational I |
Neural Stem Cells as a Developmental Candidate to Treat Alzheimer Disease |
$3,599,997 |
| University of California, Davis |
Dr. Jan Aileen Nolta PhD |
Early Translational I |
Sustained siRNA production from human MSC to treat Huntingtons Disease and other neurodegenerative disorders |
$2,615,674 |
| University of California, San Diego |
Dr. Yang Xu |
Early Translational I |
Developing induced pluripotent stem cells into human therapeutics and disease models |
$5,165,028 |
| Parkinson’s Institute |
Mr. James “Bill” William Langston Mr. |
Early Translational I |
Using patient-specific iPSC derived dopaminergic neurons to overcome a major bottleneck in Parkinson’s disease research and drug discovery |
$3,698,646 |
| University of California, Berkeley |
Dr. Ellen A. Robey |
Transplantation Immunology |
Human Immune System Mouse models as preclinical platforms for stem cell derived grafts |
$1,005,605 |
| Scripps Research Institute |
Dr. Nicholas R.J. Gascoigne |
Transplantation Immunology |
Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance |
$1,705,554 |
| Stanford University |
Dr. Kenneth Weinberg |
Transplantation Immunology |
Engineered immune tolerance by Stem Cell-derived thymic regeneration |
$1,271,729 |
| University of California, Berkeley |
Dr. David H Raulet |
Transplantation Immunology |
Inactivating NK cell reactivity to facilitate transplantation of stem cell derived tissue |
$952,896 |
| Stanford University |
Dr. Robert Negrin MD |
Transplantation Immunology |
Regulatory T cell induced tolerance to ESC transplantation |
$1,382,658 |
| University of California, San Diego |
Prof. Martin Marsala |
Transplantation Immunology |
Induction of immune tolerance after spinal grafting of human ES-derived neural precursors |
$1,387,800 |
| Cedars-Sinai Medical Center |
Dr. Terrence Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$1,119,385 |
| University of Southern California |
Dr. Terrence Christopher Town |
Transplantation Immunology |
Role of HLA in neural stem cell rejection using humanized mice |
$353,249 |
| Stanford University |
Professor Christopher H. Contag |
Transplantation Immunology |
Engineering Embryonic Stem Cell Allografts for Operational Tolerance |
$1,411,338 |
| University of California, San Diego |
Dr. Yang Xu |
Transplantation Immunology |
Induction of immune tolerance to human embryonic stem cell-derived allografts |
$1,192,680 |
| University of California, Los Angeles |
UCLA Gay M Crooks |
Transplantation Immunology |
Engineering Thymic Regeneration to Induce Tolerance |
$1,235,445 |
| University of California, Davis |
Dr. William J Murphy |
Transplantation Immunology |
Donor natural killer (NK) cells as “veto” cells to promote donor-specific tolerance |
$1,257,601 |
| Palo Alto Veterans Institute for Research |
Dr. Husein Hadeiba |
Transplantation Immunology |
Application of Tolerogenic Dendritic Cells for Hematopoietic Stem Cell Transplantation |
$733,061 |
| Escape Therapeutics, Inc |
Basil M Hantash |
Transplantation Immunology |
Development of an immune tolerant hESC source for allogeneic cell therapy applications |
$1,453,040 |
| La Jolla Institute for Allergy and Immunology |
Dr. Anjana Rao |
Transplantation Immunology |
Generation of regulatory T cells by reprogramming |
$1,464,446 |
| University of California, San Francisco |
Dr. Tippi C. MacKenzie |
Transplantation Immunology |
Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation |
$1,230,869 |
